DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C. et al.
iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): An open-label substudy of an international, multicentre, phase 3 trial.

Lancet Oncol 2017;
18: 241-50

Bibliographische Angaben herunterladen

Aufrufen in:
Aufrufen in: